CStone Pharmaceuticals (Suzhou) Co., Ltd

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Over the past roughly three years, AstraZeneca PLC’s key oncology drugs, including for lung cancer, have been facing gathering clouds in China. Not only are Chinese homegrown rivals nibbling at market

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Helsinn Extends Akynzeo Marketing